Castration-refractory prostate cancer
Xem 1-1 trên 1 kết quả Castration-refractory prostate cancer
-
: Patients diagnosed with metastatic castration-refractory prostate cancer (mCRPC) rely on a limited number of therapeutic agents resulting in a median survival of 2–3 years. A subgroup of those patients with mCRPC presents with oligoprogressive disease.
7p viorochimaru2711 01-06-2020 5 1 Download
CHỦ ĐỀ BẠN MUỐN TÌM
TOP DOWNLOAD